Category: News & Comments
Vertex: The FDA Advisory Committee Recommended Approval for Orkambi
AS WE AND PREDICTED, the FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC), voted in favor of approving Vertex's (VRTX) drug Orkambi™ (lumacaftor/ivacaftor) for people with Cystic Fibrosis (CF) ages 12 and older who have two copies of the F508del mutation in...
Read More
May 13, 2015
0
Immunotherapy at ASCO. What Do We Want to Hear?
For those who ask whether immunotherapy will have a dominant presence at ASCO, we confirm that yes; immunotherapy therapeutics will have a presence and a lot of audience, especially oncologists. There is big reason for oncologists’ interest in the subject....
Read More
May 22, 2015
0
Why Scientists Are Now Optimistic Zeroing in on Neurodegenerative Diseases
New Discoveries in Neurodegenerative Diseases Everyday is another day that can totally differ from the previous day with regard to increasing researchers’ capabilities of discovering new pathways of diseases and turning their new discoveries into far-reaching treatments. The tireless revolution...
Read More
August 24, 2017
0
Xoma: A Rally for Good Reasons
Xoma (XOMA) stock rallied surprising many but not all. We put this firm in a special table called aggressive portfolio where we put of firms with strong scientific and technological fundamentals that, for bad reasons, or trials and errors reasons...
Read More
August 25, 2017
0
Xoma: Phase 3 Eyeguard-B Trial Is Good News for Gevokizumab
Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab for Behcet’s uveitis. The study, which is sponsored by Xoma’s development partner Servier , reached its target exacerbation event as specified in the study...
Read More
May 27, 2015
0
Immunogen: Defeating Advanced Ovarian Cancer and Other Malignancies
- Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. - The firm succeeded in developing and owning the drug. - ImmunoGen is doing whatever it takes to get the drug to the patients as quickly as...
Read More
June 2, 2015
0
Gilead to Acquire Kite and Juno Stock Rallied Too
When what you predicted, preached, and wished are realized, this is good news. Today’s news is bringing all Prohost predictions into realization, Yes, Kite (KITE) is on its way to be acquired by Gilead (GILD) and yes both stocks have...
Read More
August 28, 2017
0
Biocryst: A Major Game Changing Agreement
On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website about an important agreement Biocryst Pharmaceuticals (BCRX) signed with CSL We expect the agreement to contribute a great deal into bringing effective treatments of...
Read More
June 22, 2015
0
Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles
Today it is Greece. What About Tomorrow? Can Greece's crisis devastate the biotech sector? No sane individual would think so and the hysteria cannot be called other than what it is. The biotech sector is not overvalued and its value...
Read More
June 29, 2015
0
TrovaGene: Overcoming Challenges in Cancer Immunotherapy
After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer immunotherapy), novel approaches based on new discoveries have finally demonstrated they can do the hard job. These treatments, however, are facing challenges which must...
Read More
July 8, 2015
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)